Panelists discuss how real-world evidence studies from databases like Flatiron demonstrate that second-generation Bruton ...

Panelists discuss how measurable residual disease (MRD) testing should be used primarily for prognostic information rather than routine treatment decision-making, with current guidelines recommending ...

Panelists discuss how the treatment landscape for treatment-naive patients with chronic lymphocytic leukemia (CLL) is rapidly ...

The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

An expert discusses emerging real-world strategies for managing adverse effects of antibody-drug conjugates (ADCs) in ...

Video content above is prompted by the following: The AMPLIFY study represents a landmark phase 3 trial comparing acalabrutinib-plus-venetoclax combinations with physician’s choice chemoimmunotherapy ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal ...

Katherine McDaniel, MD, discusses fertility preservation options for patients facing a cancer diagnosis and how the landscape has changed over the past two decades.

In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...